Ex-Pfizer Executive Joins Matrivax as CEO and Member of the Board of Directors
We are excited to announce that Ed Mascioli, M.D. has joined Matrivax as Chief Executive Officer (CEO) and Member of the Board of Directors. Dr. Mascioli is an experienced pharmaceutical and venture executive, and has held senior executive positions at Pfizer, Dapis Capital, Peptimmune, MPM Capital, Karos and Affinium. His leadership and business development expertise will be key in advancing our vaccine candidates through the clinic. Together, we look forward to developing our programs and building new partnerships.
Welcome to the Matrivax team, Dr. Mascioli!
May 28, 2019
Human Vaccines & Immunotherapeutics
"In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate"
Thomas J. Griffin IV, Ann Thanawastien, Robert T. Cartee, John J. Mekalanos & Kevin P. Killeen
May 27, 2019
Chemical & Engineering News
Many of our researchers have started work here shortly after graduating from the university, and many of them are still working with us today to help us make a change in bacterial disease prevention. Krista, featured in the article below, graduated a year ago with an undergraduate degree in chemistry, when she joined the Matrivax Formulations group. Sharing a passion for science and vaccine development, she quickly became a very valuable member of our team.
December 21, 2017
Matrivax Company Profile
Kevin P. Killeen